Search results
Results from the WOW.Com Content Network
In enzymology, a 5-oxoprolinase (ATP-hydrolysing) (EC 3.5.2.9) is an enzyme that catalyzes the chemical reaction. ATP + 5-oxo-L-proline + 2 H 2 O ADP + phosphate + L-glutamate. The 3 substrates of this enzyme are ATP, 5-oxo-L-proline, and H 2 O, whereas its 3 products are ADP, phosphate, and L-glutamate.
The names of pyroglutamic acid conjugate base, anion, salts, and esters are pyroglutamate, 5-oxoprolinate, or pidolate. Formation of pyroglutamic acid from N-terminal glutamine. It is a metabolite in the glutathione cycle that is converted to glutamate by 5-oxoprolinase. Pyroglutamate is found in many proteins including bacteriorhodopsin.
It thus is also a biomarker for intracellular levels of folate. The FIGLU test is used to identify vitamin B₁₂ deficiency , folate deficiency , and liver failure or liver disease . [ 1 ] [ 2 ] It is elevated with folate trapping, where it is accompanied by decreased methylmalonic acid , increased folate and a decrease in homocysteine .
Hydrolysis of the amino group of glutamine yielding glutamate and ammonium. Catalyzing enzyme: glutaminase (EC 3.5.1.2) 2. Glutamate can be excreted or can be further metabolized to α-ketoglutarate. For the conversion of glutamate to α-ketoglutarate three different reactions are possible: Catalyzing enzymes: glutamate dehydrogenase (GlDH), EC ...
Acid–base and blood gases are among the few blood constituents that exhibit substantial difference between arterial and venous values. [6] Still, pH, bicarbonate and base excess show a high level of inter-method reliability between arterial and venous tests, so arterial and venous values are roughly equivalent for these. [44]
A blood test is a laboratory analysis performed on a blood sample that is usually extracted from a vein in the arm using a hypodermic needle, or via fingerprick. Multiple tests for specific blood components, such as a glucose test or a cholesterol test , are often grouped together into one test panel called a blood panel or blood work .
To test this therapeutic hypothesis, a selective and blood-brain barrier-permeable OGA inhibitor, thiamet-G, was developed. Thiamet-G treatment was able to increase tau O -GlcNAcylation and suppress tau phosphorylation in cell culture and in vivo in healthy Sprague-Dawley rats. [ 64 ]
In May 2015, the FDA issued a warning that gliflozins can increase risk of diabetic ketoacidosis (DKA, a serious condition in which the body produces high levels of blood acids called ketones). [12] By reducing glucose blood circulation, gliflozins cause less stimulation of endogenous insulin secretion or lower dose of exogenous insulin that ...